Implications of KRAS mutations in acquired resistance to treatment in NSCLC

RATIONALE: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, Marzia, Rofi, Eleonora, Restante, Giuliana, Crucitta, Stefania, Arrigoni, Elena, Fogli, Stefano, Di Maio, Massimo, Petrini, Iacopo, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814239/
https://www.ncbi.nlm.nih.gov/pubmed/29464099
http://dx.doi.org/10.18632/oncotarget.23553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814239/
https://www.ncbi.nlm.nih.gov/pubmed/29464099
http://dx.doi.org/10.18632/oncotarget.23553

Ejemplares similares